Krystal Biotech, Inc. (KRYS)
KRYS moved a median of +0.05% 30 minutes after news, and +0.12% by the close. How KRYS actually reacts to news — the realized, point-in-time move the market made, measured across 251 labeled events over the last three years with zero look-ahead.
KRYS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 249 |
| 30-min | +0.05% | 52% | 251 |
| 60-min | +0.23% | 54% | 251 |
| to close | +0.12% | 54% | 250 |
| Middle 50% of KRYS reactions | -1.20% to +0.99% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 251 |
Half of all Krystal Biotech, Inc. news events land between -1.20% and +0.99% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KRYS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.69% | 73% | -0.33% |
| Coverage initiations | 21 | +0.01% | 57% | -0.47% |
| Rating reiterations | 105 | 0.00% | 50% | -0.21% |
| Price-target raises | 19 | +0.47% | 58% | +0.53% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how KRYS ranks against every other measured name →
That’s how KRYS usually reacts — get an email when it moves on news →Email me when KRYS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KRYS's baseline. Nothing else.
Recent KRYS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Krystal Biotech, Inc. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | -0.90% | |
| Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome | Press release | GlobeNewswire | +0.51% | -0.90% | |
| Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | -0.51% | +0.02% | |
| Form 10-Q Krystal Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.51% | -2.54% | |
| Form 8-K Krystal Biotech, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | -2.54% | |
| Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results | Press release | GlobeNewswire | +0.51% | -2.54% | |
| Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 | Press release | GlobeNewswire | -0.18% | +2.33% | |
| Form 8-K Krystal Biotech, Inc. For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +0.48% | -0.15% | |
| Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 | Press release | PR Newswire | -1.66% | +0.69% | |
| Form 8-K Krystal Biotech, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +1.67% | |
| Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa | Press release | GlobeNewswire | -1.25% | -5.28% | |
| Krystal Biotech to Present at BofA Securities 2026 Health Care Conference | Press release | GlobeNewswire | -0.26% | +2.67% | |
| Form 10-Q Krystal Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.78% | +8.04% | |
| Form 8-K Krystal Biotech, Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -2.78% | +8.04% | |
| Krystal Biotech Announces First Quarter 2026 Financial and Operating Results | Press release | GlobeNewswire | -2.78% | +8.04% | |
| Krystal Biotech to Present at Upcoming Scientific Conferences | Press release | GlobeNewswire | +0.08% | +0.57% | |
| Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026 | Press release | GlobeNewswire | +0.00% | -1.73% | |
| Form ARS Krystal Biotech, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.66% | +0.33% | |
| Form DEF 14A Krystal Biotech, Inc. For: Apr 03 | SEC filing · Form DEF | SEC EDGAR | +0.66% | +0.33% | |
| Form DEFA14A Krystal Biotech, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.66% | +0.33% | |
| Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -1.67% | -2.80% | |
| Form 10-K Krystal Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.35% | -0.40% | |
| Form 8-K Krystal Biotech, Inc. For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | -0.40% | |
| Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results | Press release | GlobeNewswire | +0.35% | -0.40% | |
| Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 | Press release | GlobeNewswire | +0.00% | -0.98% | |
| Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +1.16% | -1.46% | |
| Form 8-K Krystal Biotech, Inc. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +4.41% | |
| Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.55% | +4.41% | |
| Form 8-K Krystal Biotech, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | +2.71% | |
| Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis | Press release | GlobeNewswire | -0.20% | +2.71% | |
| Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis | Press release | GlobeNewswire | -0.74% | -0.24% | |
| Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.18% | -0.75% | |
| Form 8-K Krystal Biotech, Inc. For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | -0.94% | |
| Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +0.24% | +0.80% | |
| Form 10-Q Krystal Biotech, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.70% | +0.27% | |
| Form 8-K Krystal Biotech, Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -1.70% | +0.27% | |
| Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results | Press release | GlobeNewswire | -1.70% | +0.27% | |
| Form 8-K Krystal Biotech, Inc. For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.23% | |
| Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 | Press release | GlobeNewswire | +0.20% | -2.26% | |
| Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis | Press release | GlobeNewswire | -0.31% | +2.55% | |
| Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label | Press release | GlobeNewswire | +0.36% | +6.27% | |
| Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 | Press release | GlobeNewswire | +1.39% | +0.68% | |
| Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +0.06% | +0.05% | |
| Form 10-Q Krystal Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -9.63% | -12.26% | |
| Form 8-K Krystal Biotech, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -9.63% | -12.26% | |
| Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results | Press release | GlobeNewswire | -9.63% | -12.26% | |
| Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 | Press release | GlobeNewswire | -0.60% | — | |
| Form 8-K Krystal Biotech, Inc. For: Jul 25 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -1.88% | |
| Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa | Press release | GlobeNewswire | +0.16% | -1.88% | |
| Form 8-K Krystal Biotech, Inc. For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -1.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KRYS section they belong to.
Where else KRYS is measured.
KRYS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 251 | -0.05% | 50% |
| DOVA PHARMACEUTICALS (DOVA) | 251 | -0.10% | 46% |
| Mersana Therapeutics, Inc. (MRSN) | 251 | -0.20% | 46% |
| Soligenix, Inc. (SNGX) | 251 | -0.71% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Krystal Biotech, Inc.'s median reaction calculated?
Every labeled KRYS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 251 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of KRYS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KRYS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.